{"public_id":"co_e46975856392eeac1f0ba0b7496dbce3","status":"active","merged_into_public_id":null,"resolved_public_id":"co_e46975856392eeac1f0ba0b7496dbce3","name":"selective laser trabeculoplasty","description":"A laser procedure used to lower intraocular pressure in open-angle eye disease.","aliases":["SLT"],"types":["treatment"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"concept","status":"active","confidence":null,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","concept.status"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"papers":[{"corpus_id":72940547,"title":"Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial","citation_count":417,"url":"https://sah.borca.ai/papers/72940547"}],"claims":[{"public_id":"cl_21d8b6234c9191ad539520e32c9db0f7","text":"Selective laser trabeculoplasty achieved target intraocular pressure at more visits and avoided glaucoma surgery compared with eye drops.","corpus_id":72940547,"url":"https://sah.borca.ai/claims/cl_21d8b6234c9191ad539520e32c9db0f7"},{"public_id":"cl_ab4034422072ad9bde99342119572e22","text":"Health-related quality of life at 3 years did not differ significantly between initial selective laser trabeculoplasty and initial eye drops.","corpus_id":72940547,"url":"https://sah.borca.ai/claims/cl_ab4034422072ad9bde99342119572e22"},{"public_id":"cl_bbc83ded3fae27925c62c35fed3cd4f2","text":"From an ophthalmology cost perspective, selective laser trabeculoplasty first had a 97% probability of being more cost-effective than eye drops first at a willingness to pay of £20,000 per quality-adjusted life-year gained.","corpus_id":72940547,"url":"https://sah.borca.ai/claims/cl_bbc83ded3fae27925c62c35fed3cd4f2"},{"public_id":"cl_c8601e8c83291337b0cab21e35910499","text":"Selective laser trabeculoplasty as first treatment left 74.2% of patients requiring no drops at 36 months to keep intraocular pressure at target.","corpus_id":72940547,"url":"https://sah.borca.ai/claims/cl_c8601e8c83291337b0cab21e35910499"},{"public_id":"cl_eac13f5e6e053fb17146337a49763138","text":"Initial selective laser trabeculoplasty should be offered as first-line treatment for open angle glaucoma and ocular hypertension.","corpus_id":72940547,"url":"https://sah.borca.ai/claims/cl_eac13f5e6e053fb17146337a49763138"}],"related_concepts":[],"resolved_url":"https://sah.borca.ai/concepts/co_e46975856392eeac1f0ba0b7496dbce3","url":"https://sah.borca.ai/concepts/co_e46975856392eeac1f0ba0b7496dbce3"}